Overview

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This study aims to test the hypothesis that the artificial prolongation of the platinum-free interval with a non-platinum treatment will improve the effectiveness of overall therapy in patients with ovarian cancer progression occurring 6-12 months after first-line treatment with a platinum-derivative.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute, Naples
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Doxorubicin
Gemcitabine
Liposomal doxorubicin
Paclitaxel
Topotecan